- Conditions
- HER2 Positive Breast Cancer
- Interventions
- tucatinib, trastuzumab deruxtecan
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Alhambra, California + 92 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 13,968
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acne Vulgaris
- Interventions
- IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 20
- States / cities
- Encino, California • Lake Mary, Florida • Miami, Florida + 15 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- Minute Maid Heart Wise orange juice, Welchol
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 117
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration, Resection, Temozolomide, Triapine
- Procedure · Other · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Niharika Mettu
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
- Interventions
- Deuterium Metabolic Imaging with deuterated acetate tracer
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Contraception
- Interventions
- Gestodene/EE (FC Patch Low, BAY86-5016), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 346 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
- Interventions
- GRT-C903, GRT-R904, nivolumab, ipilimumab
- Biological
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
- Conditions
- Prostate Cancer
- Interventions
- Meditation, Prostate Biopsy, Questionnaires
- Behavioral · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms, Lymphoma
- Interventions
- MLN9708, Nelfinavir
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Laboratory Biomarker Analysis, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more
- Conditions
- Lung Neoplasms, Esophageal Lesion
- Interventions
- Olympus VE2 NIR Imaging System, Indocyanine green
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more
- Conditions
- Rotator Cuff Tear, Rotator Cuff Injury
- Interventions
- Arthroscopic rotator cuff repair with bone marrow aspirate concentrate, Arthroscopic rotator cuff repair
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 50 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- oxaliplatin, bortezomib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- VAY736, ibrutinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- La Jolla, California • Los Angeles, California • Columbus, Ohio + 2 more
- Conditions
- Other Infectious Diseases
- Interventions
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Phase 1a: CWP232291, Phase 1b: CWP232291, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- JW Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Azacitidine, Magrolimab, Venetoclax
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- CP-868,596, Docetaxel, AG-013736
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1026
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more
- Conditions
- HIV Infections
- Interventions
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Drug
- Lead sponsor
- The Wistar Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Philadelphia, Pennsylvania